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HIGHLIGHTS
 Spatiotemporal gait parameters were assessed in people with gout while adjusting for BMI and 
pain
 People with gout exhibit different gait parameters compared to matched controls
 Higher levels of functional disability are associated with gait parameters in gout
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ABSTRACT
Objectives To examine gait parameters in people with gout during different walking speeds while 
adjusting for body mass index (BMI) and foot-pain, and to determine the relationship between gait 
parameters and foot-pain and disability.
Method Gait parameters were measured using the GAITRite™ walkway in 20 gout participants and 
20 age- and sex-matched controls during self-selected and fast walking speeds. Foot-pain and 
disability was measured using the Manchester Foot Pain and Disability Index (MFPDI) which contains 
four domains relating to function, physical appearance, pain and work/leisure.
Results At the self-selected speed, gout participants demonstrated increased step time (p=0.017), 
and stance time (p=0.012), and reduced velocity (p=0.031) and cadence (p=0.013). At the fast speed,
gout participants demonstrated increased step time (p=0.007), swing time (p=0.005) and stance time 
(p=0.019) and reduced velocity (p=0.036) and cadence (p=0.009). For participants with gout, step
length was correlated with total MFPDI (r=-0.62, p=0.008), function (r=-0.65, p=0.005) and physical 
appearance (r=-0.50, p=0.041); stride length was correlated with total MFPDI (r=-0.62, p=0.008), 
function (r=-0.65, p=0.005) and physical appearance (r=-0.50, p=0.041); and velocity was correlated 
with total MFPDI (r=-0.60, p=0.011), function (r=-0.63, p=0.007) and work/leisure (r=-0.53, p=0.030).
Conclusion Gait patterns exhibited by people with gout are different from controls during both self-
selected and fast walking speeds, even after adjusting for BMI and foot-pain. Additionally, gait 
parameters were strongly correlated with patient-reported functional limitation, physical 
appearance and work/leisure difficulties, while pain did not significantly influence gait in people with 
gout.
KEYWORDS: gout, spatiotemporal gait, foot pain, disability, activities of daily living
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INTRODUCTION
Gout is a chronic disease of monosodium urate (MSU) crystal deposition, with a predilection for 
peripheral sites in the lower limbs [1, 2].  The presence of MSU crystals initiate local inflammation 
resulting in self-limiting flares of acute gouty arthritis. In the presence of persistent hyperuricaemia, 
chronic synovitis, tophi and tissue damage may develop [3-5].  People with gout report high levels of 
foot pain and disability [6-8] and experience difficulty in carrying out recreational and daily living 
activities requiring normal lower limb function [6, 9]. Furthermore, people with gout rate walking 
difficulty as a discriminatory feature of the disease [10]. This is supported by previous laboratory-
based lower limb research in which people with gout walk slower with shorter step and stride 
lengths compared to people without gout whilst walking at a comfortable self-selected speed in 
their own footwear, even in the absence of current acute arthritis [8]. However, it is currently 
unclear if patient-reported foot pain and disability is associated with the decreased functional 
abilities observed in people with gout.
Aside from pain, several other factors may also contribute to walking strategies adopted by people 
with gout. Gout is a complex disease associated with several comorbidities, including obesity [11], 
which has been shown to influence walking patterns in individuals without gout [12, 13]. However, it 
is currently unclear whether excess body mass contributes to the altered gait patterns observed in 
individuals with gout as control participants in previous research have also had elevated body mass 
[8].
Maintaining a pain-free and adequate ability to walk at a variety of speeds is fundamental for safely 
and independently performing activities of daily living. Furthermore, assessment of walking ability is 
important in developing an understanding of the onset and progression of physical disability in 
chronic disease populations, including gout [8], rheumatoid arthritis [14, 15], psoriatic arthritis [16] 
and ankylosing spondylitis [17].  The aim of this study was to examine spatiotemporal parameters of 
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gait during different walking speeds in people with gout while adjusting for BMI and foot pain, and 
to determine the relationship between spatiotemporal parameters of gait and foot-related pain and 
disability.
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METHODS
A two-arm cross-sectional study was undertaken at AUT University, New Zealand. A sample size of 
20 participants with gout and 20 age- and sex-matched controls was calculated based on data 
derived from our previous research in which the mean (SD) gait velocity was 0.90 (0.3) m/s for 
participants with gout and 1.03 (0.3) m/s for controls [8]. Power was set to 80% with a significance 
level of 5%. Gout participants were recruited from the Rheumatology Department at Auckland 
District Health Board, New Zealand. All gout participants met the 1977 preliminary American 
Rheumatism Association classification criteria for gout [18]. The age- and sex-matched controls were 
recruited by public advertising. Participants were excluded if they were experiencing an acute flare 
at the time of assessment, had a history of lower limb amputation, recent surgery or injury to the 
foot or ankle, or other rheumatic conditions. Age, gender, ethnicity, body mass index (BMI), current 
medications and co-morbidities were recorded for all participants. In addition, gout disease duration 
and clinical characteristics of gout, including flare frequency in the preceding three months and the 
presence and number of subcutaneous tophi, were recorded for the gout participants. Ethical 
approval for the study was obtained from the AUT Ethics Committee (13/100) and locality 
assessment was obtained from Auckland District Health Board (A+5891). All participants provided 
written informed consent prior to data collection.
The GAITRite™ system (CIR Systems Inc, New York, USA), which consists of a 700cm x 90cm 
electronic walkway with an active sensor area of 610cm long and 60cm wide, was used to measure 
spatiotemporal parameters of gait. The active area contains 23,040 embedded pressure-activated 
sensors with a spatial resolution of 1.27cm and a sampling rate of 120Hz. The GAITRite™ was 
positioned in a large room to allow the participant to begin walking 1m before the walkway and 
continue walking 1m past its end to ensure a constant walking velocity. Following an initial test-walk 
to familiarise the participant with the walkway, each participant was instructed to walk barefoot 
along the walkway at two different speeds specified with the following instructions: (1) ‘‘Walk at 
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your normal, preferred speed’’; and (2) ‘‘Walk as fast as you can safely walk, but do not run’’ [19]. 
These walking speeds reflect conditions that individuals are likely to face during community 
ambulation. Three repetitions for each walking speed were recorded with a 5-minute rest period 
between trials to minimise fatigue. The first and last footsteps recorded on the electronic runway 
were removed from the analysis. For the remaining steps the following parameters were calculated: 
step time (s), step length (cm), stride length (cm), swing time (s), stance time (s), velocity (cm/s) and 
cadence (steps/min). 
Patient-reported foot pain and disability was assessed using the Manchester Foot Pain and Disability 
Index (MFPDI) [20]. This 19-item index measures foot-related items in four domains associated with
functional limitation (10 items), physical appearance (2 items), pain (5 items), and work/leisure (2 
items). Statements relating to each item were answered ‘none of the time’ (scored as 0), ‘on some 
days’ (scored as 1) and ‘on most/every day(s)’ (scored as 2) in the past month. The total MFPDI 
score, as well as the total scores for each of the four domains were calculated for each participant 
with higher scores corresponding to more severe foot pain and disability. The MFPDI is a reliable [20] 
and valid tool [21] and has been used previously in gout research [6, 22].
Descriptive statistics relating to participant demographics and clinical characteristics were presented 
as mean (SD) for continuous data and frequency (%) for categorical data. All spatiotemporal data 
was reviewed for normality using random effects from a linear model through both visual and formal 
tests with the participant group (gout or control) as the independent variable. To determine the 
differences between gout and controls for each gait parameter, mixed linear models were used. A 
scaled identify covariance structure was used which assumes equal variance between each of the 
three walking trials performed at each speed. A participant-specific random effect was included to 
account for the repeated measures on right and left feet and participant-nested random effects for 
foot-side were added to the model. The final model was adjusted for BMI and MFPDI pain. 
Additionally adjustments for age and ethnicity as covariates were considered for each gait 
Page 8 of 21
Ac
ce
pte
d M
an
us
cri
pt
8
parameter only if they achieved at least 10% on an F-test. Associations between the MFPDI scores 
and gait parameters were assessed with Pearson correlation coefficients, denoted r. For the purpose 
of this analysis, gait variables measured for right and left limbs were collapsed into a single measure 
by taking the mean of the two observations. An r value of 0.1 was considered a small effect size, 0.3 
a medium effect size, and 0.5 a large effect size [23]. All data was analysed using SPSS v.20 (IBM 
Corporation) at a 5% level of significance unless otherwise noted.
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RESULTS
Table 1 presents the demographic information for the gout and control participants. Participants 
with gout were predominantly middle-aged European men with higher BMI than controls (p = 
0.006). The total mean MFPDI score was higher in participants with gout compared to controls (p < 
0.001). In the gout group, mean disease duration was 16 years, and 60% of participants had clinically 
apparent subcutaneous tophi. 
All spatiotemporal and MFPDI data conformed to a normal distribution. Neither age nor ethnicity 
reached significance for any parameters (p > 0.10) so were not included in the final model. The mean 
estimates and inferential statistics adjusted for BMI and MFPDI pain for the self-selected and fast 
walking speeds are shown in Table 2. At the self-selected walking speed participants with gout 
demonstrated increased step time (p = 0.017), increased stance time (p = 0.012), reduced velocity (p 
= 0.031) and reduced cadence (p = 0.013) compared to controls. At the fast speed participants with 
gout demonstrated increased step time (p = 0.007), increased swing time (p = 0.005), increased 
stance time (p = 0.019), reduced velocity (p = 0.036) and reduced cadence (p = 0.009) compared to 
controls. 
Table 3 presents the correlations between the MFPDI scores and the spatiotemporal parameters for 
the gout participants. Step length was negatively correlated with total MFPDI (r = -0.62, p = 0.008), 
function (r = -0.65, p = 0.005) and physical appearance (r = -0.50, p = 0.041); stride length was 
negatively correlated with total MFPDI (r = -0.62, p = 0.008), function (r = -0.65, p = 0.005) and 
physical appearance (r = -0.50, p = 0.041); and velocity was negatively correlated with total MFPDI (r 
= -0.60, p = 0.011), function (r = -0.63, p = 0.007) and work/leisure (r = -0.53, p = 0.030). Table 4 
presents the correlations between MFPDI scores and the spatiotemporal parameters for the control 
participants in which no significant correlations were observed (p > 0.05)
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DISCUSSION
The findings from this study demonstrate that people with gout exhibit altered spatiotemporal gait 
parameters during both self-selected and fast walking speeds when compared to age- and sex-
matched controls. Additionally, the results showed that shorter step and stride lengths and reduced 
walking velocity were strongly correlated with the total MFPDI score and sub-domains, including 
functional limitations.
Previous research has shown that people with gout walk slower with reduced cadence, step length 
and stride length compared to controls whilst walking at a self-selected speed in their own footwear 
[8]. Our findings for both walking speeds mirrored these results with respect to velocity and 
cadence. However, we observed no difference in step or stride length, but rather, increased step and 
stance times, with the addition of increased swing time at the fast walking speed. This suggests that 
gait impairments exhibited by people with gout, particularly in terms of spatial and time parameters
may differ between shod and barefoot conditions.
Importantly, even after adjusting for BMI and foot pain, patients with gout in the current study still 
demonstrated altered gait characteristics when compared to healthy controls. This suggests that 
other factors may contribute to gait changes in this population. This is emphasised by the absence of 
an observed correlation between foot pain and parameters of gait. Although the increased step and 
stance times may be reflective of the reduced walking velocity, they may also reflect an inability to 
efficiently transfer body weight forward during walking [24, 25]. Several existing biomechanical 
studies have proposed that people with gout may adopt apropulsive gait strategies as a result of 
reduced ankle and first metatarsophalangeal joint (1MTPJ) plantarflexion strength [6, 26], decreased 
plantar pressure beneath the hallux [8] and restricted 1MTPJ dorsiflexion motion [6]. However, 
further research is warranted to determine the relationship between these foot and ankle 
characteristics and gait patterns in this population.
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The ability to walk at not only usual speeds, but also faster speeds is a central component to daily 
mobility [27]. Faster walking speeds are fundamental in safely and independently carrying out many 
day-to-day activities including crossing the road, doing housework/gardening, and participating in 
sporting activities and active occupations. This study has shown that people with gout have difficulty 
reaching faster walking speeds compared to age- and sex-matched controls which is consistent with 
previously reported difficulties in the gout population including limited home and work productivity, 
increased dependency on others and social isolation [28-30]. 
The results from this study also showed that the patient-reported measures of foot pain and 
disability were strongly associated with parameters of gait in people with gout. Functional limitation
appeared to be the leading influence of gait, and was significantly correlated with step and stride 
lengths and velocity.  The association between foot pain and decreased functional abilities has been 
demonstrated in other long term chronic disease conditions [31-36]. Interestingly, foot pain was not 
associated with gait characteristics. However, it should be acknowledged that the participants with 
gout were not experiencing current symptoms of acute arthritis at the time of the study. It may be
that pain/fear-avoidance mechanisms may be persistent or learned strategies adopted by patients in 
an attempt to prevent triggering an episode of acute arthritis. This behaviour has been illustrated in 
qualitative research in which people with gout report an inability to participate in physical activities 
with family and friends for fear of triggering a flare [28, 37].
This study should be considered in light of some limitations. Firstly, participants were recruited from 
secondary care rheumatology clinics, and had long disease duration with high frequency of 
tophaceous disease.  These results may not be generalizable to less severe gout treated in primary 
care. Furthermore, our gout cohort was relatively small and may not be representative of secondary 
care patients. We also did not directly assess the extent of joint damage or tophus deposition 
through imaging in our gout participants, and it is likely that our clinical observations underestimate 
the degree of joint involvement. Next, the causal link between gait characteristics and foot pain 
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cannot be determined from the cross-sectional design. It must also be acknowledged that the 
patient-reported outcome measure used in this study represented a reflection of pain and disability 
in the past month and not during the measurement of gait data. Furthermore, the MFPDI focused on 
foot-related pain and disability and did not recognise pain or other musculoskeletal disorders at 
other joints involved in gait. Future studies may investigate the relationship between gait strategies 
in people with gout and other lower limb biomechanical characteristics including lower joint 
function and muscle strength. Future longitudinal research may investigate the effect of 
pharmacological interventions, particularly urate lowering therapy on foot function. The 
contribution of gout-specific features to walking strategies, including tophus formation in lower limb 
joints, would also provide important insight into the mechanisms behind the functional impairment 
observed in the gout population.
CONCLUSION
The findings from this study demonstrate that gait patterns exhibited by people with gout are 
significantly different from age- and sex-matched controls during both self-selected and fast walking 
speeds, even after adjusting for BMI and foot pain. Additionally, higher levels of self-reported 
functional limitations, physical appearance and work/leisure difficulties were strongly correlated 
with parameters of gait, including reduced step and stride lengths and slower walking velocity.
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Table 1: Demographics & clinical characteristics
Variable Control Gout p
N 20 20
Gender, male, n (%) 19 (95%) 19 (95%) 1.00
Age, years, mean (SD) 53 (12) 60 (7) 0.06
Ethnicity, n (%) European 20 (100%)
Maori 0 (0%)
Pacific 0 (0%)
Asian 0 (0%)
European 12 (60%)
Maori 1 (5%)
Pacific 3 (15%)
Asian 4 (20%)
0.004
Height, m, mean (SD) 1.75 (0.07) 1.75 (0.07) 0.904
BMI, kg/m2, mean (SD) 26.7 (4.3) 31.5 (5.9) 0.006
Diuretic use, n (%) 1 (5%) 3 (15%) 0.640
NSAID use, n (%) 0 (0%) 12 (60%) 0.998
Prednisone use, n (%) 0 (0%) 2 (10%) 0.998
Hypertension, n (%) 6 (30%) 12 (60%) 0.061
Cardiovascular disease, n (%) 1 (5%) 5 (25%) 0.110
Diabetes, n (%) 1 (5%) 4 (20%) 0.180
Microscopically proven gout - 4 (20%) -
Disease duration, years, mean (SD) - 16 (11) -
Serum urate, mmol/l, mean (SD) - 0.37 (0.15) -
Flares in preceding 3 months, mean (SD) - 1.1 (1.6) -
Any subcutaneous tophi, n (%) - 12 (60%) -
Subcutaneous tophus count,  mean (SD) - 3.9 (6.1) -
Tophus site, n (%) - Elbow, 7 (35%)
Hand, 9 (45%)
Knee, 1 (5%)
Ankle, 3 (15%)
1MTP, 4 (20%)
Toes, 4 (20%)
-
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Colchicine use, n (%) - 9 (45%) -
Urate lowering therapy, n (%) - 18 (95%) -
Allopurinol use, n (%) - 16 (80%) -
Febuxostat use, n (%) 2 (10%)
Probenecid use, n (%) - 2 (10%) -
MFPDI, total score, mean (SD) 2.1 (4.3) 12.4 (8.6) <0.001
         Function, mean (SD) 0.9 (2.0) 6.5 (4.6) <0.001
         Physical appearance, mean (SD) 0.0 (0.0) 1.1 (1.2) <0.001
          Pain, mean (SD) 1.0 (2.2) 3.4 (2.5) 0.005
          Work/Leisure, mean (SD) 0.2 (0.4) 1.2 (1.3) 0.001
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Table 2: Mean estimates and inferential statistics
Control Gout Difference (95%CI) p
Step time (s)
Self-selected 0.54 0.59 0.05 (0.01 – 0.09) 0.017
Fast 0.43 0.49 0.06 (0.02 –0.10) 0.007
Step length (cm)
Self-selected 68.1 70.4 -2.2 (-8.4 – 3.9) 0.459
Fast 85.3 82.1 -3.2 (-11.4 – 5.0) 0.433
Stride length (cm)
Self-selected 141.1 136.5 -4.6 (-17.1 – 7.9) 0.456
Fast 170.9 164.5 -6.5 (-22.9– 10.0) 0.393
Swing Time (s)
Self-selected 0.42 0.45 0.03 (-0.01 – 0.07) 0.164
Fast 0.36 0.40 0.06 (0.02 – 0.08) 0.005
Stance Time (s)
Self-selected 0.65 0.72 0.07 (0.02 – 0.12) 0.012
Fast 0.50 0.57 0.07 (0.01 – 0.13) 0.019
Velocity (cm/s)
Self-selected 132.7 117.4 -15.3 (-29.2 – -1.5) 0.031
Fast 201.9 171.4 -30.4 (-58.7– -2.1) 0.036
Cadence (steps/min)
Self-selected 113.0 103.3 -9.7 (-17.2 – -2.2) 0.013
Fast 141.2 124.5 -16.7 (-28.8 – 4.6) 0.009
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Table 3: Correlations between gait parameters and MFPDI scores for the gout group
Spatiotemporal gait parameters, Pearson’s r (p)
Step 
Time
Step 
Length
Stride 
Length
Swing 
Time
Stance 
Time
Velocity Cadence
-0.16 -0.62 -0.62 0.16 0.30 -0.60 -0.14
Total
(0.531) (0.008) (0.008) (0.530) (0.243) (0.011) (0.592)
-0.14 -0.65 -0.65 0.17 0.30 -0.63 -0.14
Function
(0.600) (0.005) (0.005) (0.508) (0.251) (0.007) (0.592)
-0.37 -0.50 -0.50 -0.10 0.05 -0.38 0.13
Physical Appearance
(0.149) (0.041) (0.040) (0.692) (0.855) (0.137) (0.633)
-0.09 -0.42 -0.42 0.17 0.28 -0.43 -0.18
 Pain
(0.735) (0.094) (0.093) (0.513) (0.283) (0.082) (0.494)
0.06 -0.46 -0.46 0.31 0.38 -0.53 -0.27
Work/ Leisure
(0.811) (0.064) (0.064) (0.220) (0.131) (0.030) (0.301)
Table 4: Correlations between gait parameters and MFPDI scores for the control group
Spatiotemporal gait parameters, Pearson’s r (p)
Step 
Time
Step 
Length 
Stride 
Length
Swing 
Time
Stance 
Time
Velocity Cadence
0.22 0.06 0.04 0.08 0.28 -0.13 -0.25
Total
(0.360) (0.821) (0.859) (0.742) (0.240) (0.591) (0.303)
0.17 0.23 0.21 0.10 0.18 0.01 -0.18
Function
(0.478) (0.352) (0.395) (0.670) (0.453) (0.982) (0.452)
- - - - - - -
Physical Appearancea
- - - - - - -
0.28 -0.15 -0.15 0.07 0.38 -0.29 -0.32
 Pain
(0.253) (0.555) (0.548) (0.776) (0.110) (0.231) (0.189)
0.19 -0.07 -0.08 0.04 0.28 -0.18 -0.22
Work/ Leisure
(0.430) (0.772) (0.755) (0.887) (0.246) (0.473) (0.361)
aVariable redundant
